Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Atovaquone And Proguanil Hydrochloride
Brand Name
Atovaquone And Proguanil Hydrochloride
Generic Name
Atovaquone And Proguanil Hydrochloride
Active Ingredient
AtovaquoneCategory
Antimalarial [EPC]
Variants
6
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Atovaquone And Proguanil Hydrochloride, you must consult a qualified healthcare professional.
| 250 mg/1 | TABLET, FILM COATED | ORAL | 68001-245 |
| 250 mg/1 | TABLET, FILM COATED | ORAL | 0378-4162 |
| 62.5 mg/1 | TABLET, FILM COATED | ORAL | 0378-4160 |
Detailed information about Atovaquone And Proguanil Hydrochloride
Atovaquone is a potent antiprotozoal medication used primarily for the prevention and treatment of Pneumocystis jirovecii pneumonia and malaria. It belongs to the hydroxynaphthoquinone class and works by disrupting the mitochondrial electron transport chain in parasites.
Dosage for Atovaquone varies significantly based on the condition being treated and the specific formulation used. Healthcare providers typically follow these standardized protocols:
Atovaquone use in children is well-established but requires careful weight-based calculations:
For PCP treatment using the suspension, no specific dose adjustment is typically required for mild to moderate renal impairment. However, for malaria prevention/treatment using the combination tablet (Atovaquone/Proguanil), the drug is contraindicated (should not be used) in patients with severe renal impairment (Creatinine Clearance < 30 mL/min) because the proguanil component can accumulate to toxic levels.
Atovaquone has not been extensively studied in patients with severe hepatic (liver) impairment. However, since the drug is not metabolized by the liver and is primarily excreted unchanged in the feces, significant dose adjustments are often not required. Nevertheless, healthcare providers will monitor liver function tests (LFTs) closely in these patients.
Clinical trials did not include sufficient numbers of patients aged 65 and over to determine if they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.
If you miss a dose, take it as soon as you remember with food. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this can increase the risk of side effects.
There is no specific antidote for Atovaquone overdose. In cases of accidental ingestion of large amounts, patients should seek emergency medical care. Symptoms of overdose may include an exaggeration of common side effects, such as severe rash or gastrointestinal distress. Because the drug is highly protein-bound, dialysis is unlikely to be effective in removing Atovaquone from the blood.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as this can lead to the development of drug-resistant infections.
Atovaquone is generally better tolerated than alternative treatments like TMP-SMX, but side effects are still common, particularly during the 21-day PCP treatment course. Common reactions include:
The most critical safety consideration for Atovaquone is its absorption dependency. If a patient is unable to eat or has chronic diarrhea/malabsorption issues, Atovaquone plasma levels may never reach the concentration needed to kill the parasite. In such cases, healthcare providers must consider alternative intravenous (IV) therapies. Patients should be aware that Atovaquone is not a substitute for IV therapy in cases of severe, life-threatening PCP.
There are currently no FDA black box warnings for Atovaquone. It is considered a secondary treatment option for PCP, primarily reserved for those who cannot tolerate first-line sulfonamide therapy.
While Atovaquone has few absolute contraindications regarding drug interactions, certain combinations are avoided because they drastically reduce the efficacy of Atovaquone:
Atovaquone is contraindicated in patients who have a known hypersensitivity (severe allergy) to the drug or any of its components (such as the ingredients in the suspension). A history of anaphylaxis, Stevens-Johnson Syndrome, or severe erythema multiforme in response to Atovaquone precludes its future use.
For the combination product (Atovaquone/Proguanil), an absolute contraindication exists for patients with severe renal impairment (Creatinine Clearance < 30 mL/min). This is due to the proguanil component, which is primarily cleared by the kidneys; in severe kidney disease, proguanil can reach toxic levels that cause bone marrow suppression and other systemic toxicities.
Atovaquone is classified as Pregnancy Category C under the older FDA system. There are no adequate and well-controlled studies in pregnant women. Animal studies in rabbits using high doses (3 times the human dose) showed evidence of maternal toxicity but not direct fetal malformations. However, because PCP and malaria are themselves life-threatening to both the mother and the fetus, the CDC and other health organizations suggest that Atovaquone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally not the first choice for malaria prophylaxis in pregnant women; mefloquine or chloroquine are often preferred depending on the region.
It is not known whether Atovaquone is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Atovaquone is administered to a nursing woman. In animal studies, Atovaquone was found in the milk of lactating rats at concentrations 30% of those in the mother's plasma. The decision to breastfeed while taking Atovaquone should be made in consultation with a pediatrician, weighing the benefits of breastfeeding against the potential for drug exposure in the infant.
Atovaquone is a highly lipophilic ubiquinone (Coenzyme Q10) analog. Its primary molecular target is the cytochrome bc1 complex (Complex III) within the mitochondrial electron transport chain of the parasite. By competitively binding to the 'Qo' site of the cytochrome b subunit, Atovaquone inhibits the oxidation of reduced ubiquinone. This blockade halts the flow of electrons to cytochrome c.
In protozoa like Plasmodium and Pneumocystis, the electron transport chain is not primarily used for oxidative phosphorylation (ATP production) but is essential for the regeneration of ubiquinone, which acts as an electron acceptor for the enzyme dihydroorotate dehydrogenase (DHODH). DHODH is a key enzyme in the de novo pyrimidine biosynthetic pathway. By inhibiting the bc1 complex, Atovaquone causes a secondary inhibition of DHODH, leading to a failure in pyrimidine synthesis, an inability to replicate DNA, and eventual parasite death.
Atovaquone exhibits a slow onset of action compared to some other antiprotozoals. It is considered 'protozoocidal' (kills the parasite) rather than just 'protozoostatic' (inhibits growth). There is a clear dose-response relationship, but it is heavily confounded by the drug's variable absorption. The duration of effect is prolonged due to the drug's long half-life, which allows for once-daily dosing in prophylaxis.
Common questions about Atovaquone And Proguanil Hydrochloride
Atovaquone is primarily used to treat and prevent Pneumocystis jirovecii pneumonia (PCP), a serious lung infection that affects people with weakened immune systems, such as those with HIV or organ transplants. It is also used in combination with another drug, proguanil, to treat and prevent malaria. Because it works differently than standard antibiotics, it is often prescribed for patients who are allergic to sulfa drugs. Your doctor will determine the appropriate use based on your specific health needs and the type of infection being targeted. It is essential to take it exactly as prescribed to ensure the infection is fully cleared.
The most frequently reported side effects of Atovaquone include skin rash, nausea, diarrhea, and headache. In clinical trials, up to 20% of patients experienced a rash, which is often itchy but usually manageable. Gastrointestinal issues like vomiting and stomach pain are also common, particularly because the drug must be taken with fatty food, which can be hard for some patients to tolerate. Other common effects include fever, insomnia, and a cough. Most of these side effects are mild to moderate, but you should always report new or worsening symptoms to your healthcare provider.
There is no known direct interaction between Atovaquone and alcohol that would make the drug stop working. However, healthcare providers generally advise against heavy alcohol consumption while taking this medication because both alcohol and Atovaquone can affect the liver. Additionally, alcohol can worsen the stomach upset, nausea, and diarrhea that are common side effects of Atovaquone. If you are being treated for a serious infection like PCP or malaria, your body needs to be well-hydrated and rested, and alcohol can interfere with the recovery process. Always consult your doctor about your specific alcohol consumption habits.
Atovaquone is classified as Pregnancy Category C, meaning there are no definitive studies in humans to prove it is safe for a developing fetus. Animal studies have shown some risks at very high doses, but the risks of untreated malaria or PCP during pregnancy are often much higher for both the mother and the baby. Doctors typically only prescribe Atovaquone during pregnancy if the benefits clearly outweigh the potential risks. If you are pregnant or planning to become pregnant, it is vital to discuss all options with your healthcare provider. They may recommend alternative medications depending on your specific situation and the severity of the infection.
Atovaquone begins working at the molecular level shortly after the first few doses, but it takes time for the drug levels to build up in your bloodstream. For the treatment of PCP, a full 21-day course is required, and patients may not see significant improvement in their symptoms for several days. For malaria treatment, it is typically taken for three consecutive days. Because the drug has a very long half-life, it remains in your system for several days after the last dose. It is crucial to finish the entire prescription even if you start feeling better within the first few days.
You should never stop taking Atovaquone suddenly without consulting your doctor, especially if you are taking it to treat an active infection like PCP or malaria. Stopping the medication early can allow the remaining parasites to multiply, leading to a relapse of the infection that may be harder to treat. In the case of malaria prevention, stopping the drug too soon after leaving a high-risk area could leave you unprotected. If you are experiencing severe side effects, your doctor can help you transition to a different medication safely. Always follow the full course of therapy as directed.
If you miss a dose of Atovaquone, take it as soon as you remember, but only if you can take it with a meal or a high-fat snack. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for the missed one, as this can increase your risk of side effects like nausea and vomiting. Consistency is key with Atovaquone because maintaining steady drug levels in your blood is necessary to keep the infection under control. If you miss multiple doses, contact your healthcare provider for guidance.
Weight gain is not a recognized or common side effect of Atovaquone. In fact, many patients taking Atovaquone for serious infections like PCP may actually experience weight loss due to the underlying illness or the gastrointestinal side effects of the drug, such as nausea and diarrhea. If you notice rapid or unusual weight gain while taking this medication, it is more likely related to another condition or medication you are taking. You should discuss any significant changes in your weight with your healthcare provider to determine the underlying cause. Monitoring your weight is a standard part of managing chronic illnesses.
Atovaquone can interact with several other medications, which may make it less effective. Specifically, drugs like rifampin (for TB) and certain antibiotics like tetracycline can significantly lower the amount of Atovaquone in your blood. It can also interact with some HIV medications and metoclopramide (used for nausea). However, because it is not processed by the liver's main enzyme system (CYP450), it has fewer interactions than many other drugs. You must provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking to ensure a safe treatment plan.
Yes, Atovaquone is available as a generic medication in both its oral suspension form and in the combination tablet with proguanil. Generic versions are required by the FDA to have the same active ingredients, strength, and effectiveness as the brand-name versions (like Mepron or Malarone). Choosing the generic version can often significantly reduce the cost of treatment. However, regardless of whether you take the brand or the generic, the requirement to take the medication with a high-fat meal remains the same. Check with your pharmacist or insurance provider to see which version is covered under your plan.
Other drugs with the same active ingredient (Atovaquone)
> Warning: Stop taking Atovaquone and call your doctor immediately if you experience any of the following serious symptoms:
Atovaquone is typically used for short-term treatment (21 days) or intermittent prophylaxis. Long-term use (months to years) for PCP prophylaxis is generally considered safe, but patients may experience chronic mild elevations in liver enzymes or persistent mild GI upset. There is no evidence currently suggesting that Atovaquone causes long-term organ damage or secondary cancers, but regular monitoring of blood counts and liver function is standard clinical practice for those on long-term therapy.
As of 2026, the FDA has not issued any Black Box Warnings for Atovaquone. However, the lack of a black box warning does not imply the drug is without risk. The primary clinical concern remains the risk of treatment failure if the drug is not taken with adequate fat intake.
Report any unusual symptoms or changes in your health to your healthcare provider promptly. Clinical monitoring often involves baseline and periodic blood tests to ensure the medication is being tolerated well by your liver and bone marrow.
Patients taking Atovaquone, especially for the 21-day treatment course, typically require the following monitoring:
Atovaquone is not known to cause significant sedation or cognitive impairment. Most patients are able to drive and operate machinery safely. However, if you experience dizziness or severe headache, you should avoid these activities until you know how the medication affects you.
There is no direct contraindication between Atovaquone and alcohol. However, alcohol can irritate the stomach lining and may worsen the gastrointestinal side effects (nausea, diarrhea) associated with Atovaquone. Furthermore, both alcohol and Atovaquone can stress the liver; therefore, excessive alcohol consumption is discouraged during treatment.
Atovaquone does not require a tapering schedule and is not associated with a withdrawal syndrome. However, stopping the medication early during a treatment course for PCP or malaria is highly dangerous, as it allows the remaining parasites to multiply, potentially leading to a relapse of the infection and the development of drug resistance.
> Important: Discuss all your medical conditions, especially liver disease or gastrointestinal disorders, with your healthcare provider before starting Atovaquone.
Atovaquone is not known to interfere with common laboratory tests, such as urine glucose or pregnancy tests. However, it may cause false elevations in some liver function assays if the drug's yellow pigment interferes with colorimetric readings, though this is rare with modern lab equipment.
Mechanism Summary: Most Atovaquone interactions are pharmacokinetic in nature, specifically affecting the absorption or clearance of the drug. Because Atovaquone is not a CYP450 substrate, it avoids the most common type of drug-drug interactions, making it a relatively safe choice for patients on complex polypharmacy regimens, provided their GI absorption is monitored.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those for HIV, TB, or stomach issues.
Atovaquone does not typically show cross-sensitivity with sulfonamides (sulfa drugs). This is one of its primary clinical advantages, as it can be safely used in the majority of patients who have had life-threatening reactions to Bactrim or Septra.
> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and allergy history, before prescribing Atovaquone.
Atovaquone suspension is FDA-approved for the prevention of PCP in children as young as 1 month of age. For the treatment of PCP, safety and effectiveness have been established in adolescents aged 13 and older. In younger children, the drug is often used off-label for PCP treatment when other options fail. The combination tablet for malaria is approved for children weighing 5 kg (approx. 11 lbs) or more. Growth and development do not appear to be negatively impacted by short-term Atovaquone use.
Clinical studies of Atovaquone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, elderly patients may have a higher prevalence of renal or hepatic impairment and are more likely to be taking multiple medications (polypharmacy). Therefore, monitoring should be more frequent, and the lowest effective dose should be utilized. There is no specific evidence that Atovaquone increases fall risk or cognitive decline in the elderly.
In patients with mild to moderate renal impairment, the pharmacokinetics of Atovaquone are not significantly altered. However, as noted previously, the combination tablet containing proguanil is strictly contraindicated in severe renal failure (CrCl < 30 mL/min). For patients on hemodialysis, Atovaquone is not significantly cleared by the dialysis process due to its high protein binding.
There are no specific dosing recommendations for patients with hepatic impairment. However, because the drug is excreted in the bile, severe biliary obstruction could theoretically lead to drug accumulation. Patients with Child-Pugh Class C cirrhosis should be monitored closely for signs of toxicity.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
| Parameter | Value |
|---|---|
| Bioavailability | 23% (Suspension with food); <10% (Fasting) |
| Protein Binding | >99.9% (Primarily Albumin) |
| Half-life | 50–70 Hours (Adults); 30–40 Hours (Children) |
| Tmax | 1 to 8 Hours (Highly variable) |
| Metabolism | Negligible (No CYP involvement) |
| Excretion | Fecal (>94%); Renal (<0.6%) |
Atovaquone is the only member of the hydroxynaphthoquinone class currently in widespread clinical use. While it is functionally related to other antimalarials, its specific site of action on the bc1 complex makes it unique. It is often grouped with other 'Mitochondrial Inhibitors' in parasitology textbooks.